Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06372496 · ClinicalTrials.gov registry record · Phase 4
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
A Phase 4 study of Asthma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 4
- Development phase
- 1,357
- Enrollment target
- 20
- Study locations
NCT06372496: Active Phase 4 study of Asthma, sponsored by GlaxoSmithKline.
NCT06372496 is a Phase 4 study of Asthma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 1,357 participants, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06372496, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,357 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
Conditions Studied
Interventions
- DRUG Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
- DRUG Inhaled corticosteroids/long-acting beta-2 agonists
Study Locations (20)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - North Miami Beach
- GSK Investigational Site - Orlando
- GSK Investigational Site - Palm Springs
- GSK Investigational Site - Port Charlotte
- GSK Investigational Site - Tallahassee
North Carolina
- GSK Investigational Site - Asheville
- GSK Investigational Site - Charlotte
Arkansas
- GSK Investigational Site - Little Rock
California
- GSK Investigational Site - Newport Beach
Illinois
- GSK Investigational Site - Normal
Louisiana
- GSK Investigational Site - New Orleans
Maine
- GSK Investigational Site - Bangor
Michigan
- GSK Investigational Site - Warren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,357 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 4 |
What the registry record for NCT06372496 still lists
NCT06372496 is an interventional study that assigns participants to a tested intervention. Its 1,357 participants enrollment target places it among the larger protocols in the corpus, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate is the first listed.
NCT06372496 names 20 study sites across 12 states, led by Florida, North Carolina, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06372496 about?
NCT06372496 is a clinical study titled "Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma". The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
What is the current status of trial NCT06372496?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 1,357 participants. The study started on 2024-04-16. Estimated completion is 2026-01-22.
What conditions does trial NCT06372496 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06372496?
The interventions under investigation include: Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (DRUG), Inhaled corticosteroids/long-acting beta-2 agonists (DRUG).
Who is sponsoring clinical trial NCT06372496?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06372496 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06372496's enrollment target sits among peer trials
1,357 29th of 374 higher than 346 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI